Tarveda Therapeutics is a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin® miniature drug conjugates, for the treatment of patients with various solid tumor malignancies. Tarveda’s Pentarin® miniature drug conjugates are designed to deeply penetrate solid tumors, selectively bind to the desired tumor targets and accumulate their anti-cancer payloads directly in tumor cells. The payload is retained and then released over time causing the anti-cancer payload to become active in the tumor.
Tarveda’s first clinical program, PEN-866, is the initial candidate from its Heat Shock Protein 90 (“HSP90”) binding miniature drug conjugate platform. HSP90 is a molecular chaperone that is highly activated in the harsh tumor environment, but which remains relatively dormant in normal tissue. Up to 75% of solid tumors have activated HSP90, and small molecule drugs that target activated HSP90 have desirable binding properties in solid tumors. PEN-866 is a miniature drug conjugate that selectively binds to the activated form of HSP90 linked to a topoisomerase 1 inhibitor (SN-38), a potent anti-cancer payload. PEN-866 has commenced its Phase 2a trial in various types of solid tumors. In addition to PEN-866, Tarveda is developing additional miniature drug conjugates on its HSP90 binding miniature drug conjugate platform to target other promising anti-cancer payloads such as kinase inhibitors and radioisotopes to solid tumors.
Company Details
- Employees
- 6
- Founded
- -
- Address
- 134 Coolidge Avenue, Watertown,ma 02472,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.tarvedatx.com/
- HQ
- Watertown, MA
Tarveda Therapeutics Questions
Tarveda Therapeutics's website is https://www.tarvedatx.com/
Tarveda Therapeutics's LinkedIn profile is https://www.linkedin.com/company/tarveda-therapeutics
Tarveda Therapeutics has
6 employees.
View email and phone details for 6
employees at Tarveda Therapeutics.
Tarveda Therapeutics's industry is
Biotechnology Research
Tarveda Therapeutics's top competitors are
Regeneron,
Kestrel Therapeutics,
Alnylam Pharmaceuticals,
Tessera Therapeutics,
C4 Therapeutics, Inc.,
Anchiano Therapeutics,
Strand Therapeutics,
Prime Medicine, Inc.,
Mirai Bio,
Beam Therapeutics.
Tarveda Therapeutics's categories are Biotechnology Research
Tarveda Therapeutics's founding year is 2011
